dc.contributor.author | Abuga, K. O. | |
dc.contributor.author | Ongarora, D. B | |
dc.contributor.author | Njogu, P. M | |
dc.contributor.author | Amugune, B. K. | |
dc.contributor.author | Okaru, A. O. | |
dc.contributor.author | Ndwigah, S. N. | |
dc.contributor.author | Kibwage, I. O. | |
dc.date.accessioned | 2023-05-15T07:16:32Z | |
dc.date.available | 2023-05-15T07:16:32Z | |
dc.date.issued | 2023-03-02 | |
dc.identifier.citation | Abuga, K. O., Ongarora, D. B., Njogu, P. M., Amugune, B. K., Okaru, A. O., Ndwigah, S. N., & Kibwage, I. O. (2022). Quality Control Report of Drugs Analyzed in the Drug Analysis and Research Unit During the Period 2016-2020. The East and Central African Journal of Pharmaceutical Sciences, 25(1), 3-8. | en_US |
dc.identifier.uri | http://uonjournals.uonbi.ac.ke/ojs/index.php/ecajps/article/view/1435 | |
dc.identifier.uri | http://erepository.uonbi.ac.ke/handle/11295/163604 | |
dc.description.abstract | During the five-year period covering 2016-2020, the Drug Analysis and Research Unit
(DARU) received and processed 326 drug samples. Of these samples, 32.5% were locally
manufactured, 65.7% imported and 1.8% of undeclared origin. Samples were analyzed
according to compendial and/or in-house specifications. The overall non-compliance rate
was 1.8% (0.6% locally manufactured, 0.9% imported and 0.3% drugs of undeclared
origin). Full analytical compliance was recorded with anti-emetics. spasmolytics,
antihypertensives, ophthalmics, anti-infectives, analgesics, anti-inflammatory agents,
anti-epileptics, nootropics, anaesthetics, respiratory drugs, genitourinary drugs,
anticancers, dermatologicals, immunomodulatory drugs, vaccines and excipients.
However, one sample each of anti-ulcers, hypoglycemics, opioids and herbals as well as
two samples of antiseptics did not comply with specifications. This represents the lowest
failure rate of samples analyzed in DARU and presented as pentad reports since the year
1991. | en_US |
dc.language.iso | en_US | en_US |
dc.publisher | ECAJPS | en_US |
dc.subject | DARU, specifications, drug class, market authorization, adulteration, substandard and falsified medicine | en_US |
dc.title | Quality control report of drugs analyzed in the drug analysis and research unit during the period 2016-2020 | en_US |
dc.type | Article | en_US |